At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 79 enrolled
Drug / intervention
Vehicle +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Trial to Evaluate ET-01 in Subjects With Lateral Canthal Lines
In Brief
A Phase 2 clinical trial evaluating Vehicle and botulinum toxin, Type A for Lateral Canthal Lines and Crow's Feet. Completed, enrolled 79 participants across 6 sites.
Detailed Summary
This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLateral Canthal Lines, Crow's Feet
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartAug 2018
First PostedAug 2018
Primary CompletionNov 2018
Study CompletionApr 2019
TodayJul 2026
First PostedAug 31, 2018
Enrollment StartAug 16, 2018
Primary CompletionNov 9, 2018
Study CompletionApr 11, 2019
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 7.8 years ago
Interventions
Vehiclebiological
Vehicle Formulation
botulinum toxin, Type Abiological
botulinum toxin, Type A, lower Dose 1, administered once, topically, at Baseline
botulinum toxin, Type Abiological
botulinum toxin, Type A, higher Dose 2, administered once, topically, at Baseline